



# Intermountain Healthcare Recruiting Patients for ASCO's Groundbreaking TAPUR Clinical Trial

*ASCO Trial at Intermountain Medical Center and Dixie Regional Will Learn From Use of Approved Targeted Cancer Therapies Matched to Tumor Genomic Profile*

SALT LAKE CITY, UT, UNITED STATES, November 21, 2016 /EINPresswire.com/ -- November 21, 2016 -- [Intermountain Healthcare](#) announced today it is recruiting patients for the American Society of Clinical Oncology's (ASCO) first-ever clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The trial will evaluate molecularly targeted cancer drugs and collect data on clinical outcomes to learn about additional uses of these drugs outside of indications already approved by the Food and Drug Administration (FDA). Patients enrolled in the study will have access to these cancer drugs at no cost. Patients interested in participating in the study are encouraged to review the eligibility requirements on the TAPUR website and speak to their physicians.

Intermountain Medical Center in Salt Lake City and Dixie Regional Medical Center in St. George are the only Utah entities participating in the ASCO trial.

"We are excited to be participating," said Craig Nichols, MD, Intermountain Medical Center Department of Oncology main investigator. "We thank ASCO for bringing the opportunity for molecularly-driven solutions to more cancer patients."

"We have been working to target medications to specific tumors for some time," said Lincoln Nadauld, MD, Director of Intermountain Healthcare's [Precision Genomics](#) program. "The ASCO clinical trial gives us the ability to collaborate with other healthcare providers, empowering physicians and patients in finding solutions to cancer without increasing costs."

Because TAPUR includes broader eligibility criteria and allows the treating physician greater discretion, it will include a broader patient population than many clinical trials. Eligible participants include those who have an advanced solid tumor, multiple myeloma, or B cell non-Hodgkin lymphoma, who are no longer benefitting from standard anti-cancer treatments or for whom no acceptable standard treatment is available.

"This trial will help evaluate whether certain targeted therapies offer benefits when no established options remain and provide access to these therapies for patients who participate," said ASCO President Daniel F. Hayes, MD, FASCO. "With TAPUR, these patients have the potential to benefit from targeted therapies that have already demonstrated effectiveness in other cancer types. Like other clinical trial participants, they can also help tomorrow's patients."

An Institutional Review Board has approved the study, and ASCO has established a Steering Group and an independent Data and Safety Monitoring Board to oversee the trial. A Molecular Tumor Board also is available to help identify treatment options for patients based on the genomic profile of their tumor. Patients and patient advocates are included in each of these groups and play a central role in providing direction and guidance regarding all aspects of the study. ASCO will publish the study's findings in peer-reviewed journals to inform clinical practice and future research.

Patients can find study information such as general eligibility criteria, participating locations, and contact information for the study team at [www.TAPUR.org](http://www.TAPUR.org). The TAPUR Study also is registered on [clinicaltrials.gov](http://clinicaltrials.gov) (NCT 02693535), which includes a full list of inclusion/exclusion criteria and other information. Researchers and practices interested in participating can fill out the TAPUR Study Site Questionnaire or contact study organizers at: <http://www.tapur.org/contact-us>.

###

#### About Intermountain Healthcare

Intermountain Healthcare is a Utah-based, not-for-profit system of 22 hospitals, 185 clinics, a Medical Group with about 1,500 employed physicians and advanced practitioners, a health plans group called SelectHealth, and other health services. With a mission of helping people live the healthiest lives possible®, Intermountain is widely recognized as a leader in transforming healthcare through high quality and sustainable costs. For more information about Intermountain, visit [intermountainhealthcare.org](http://intermountainhealthcare.org), read our blogs at [intermountainhealthcare.org/blogs](http://intermountainhealthcare.org/blogs), connect with us on Twitter at <https://twitter.com/Intermountain> and on Facebook at <https://www.facebook.com/Intermountain>.

#### About ASCO

Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at [www.ASCO.org](http://www.ASCO.org), explore patient education resources at [www.Cancer.Net](http://www.Cancer.Net), and follow us on Facebook, Twitter, LinkedIn, and YouTube.

Lance Madigan  
Intermountain Healthcare  
(801) 442-3217  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.